Wei-Ting Hwang, Ph.D.

faculty photo
Professor of Biostatistics in Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania
Member, Biomedical Graduate Studies (BGS), University of Pennsylvania Perelman School of Medicine
Member, Clinical Trials Scientific Review and Monitoring Committee (CTSRMC), University of Pennsylvania Abramson Cancer Center
Senior Scholar, Center for Clinical Epidemiology and Biostatistics (CCEB), University of Pennsylvania Perelman School of Medicine
Associate Member, Abramson Cancer Center (ACC), University of Pennsylvania
Associate Fellow, Center for Health Behavior Research (CHBR), University of Pennsylvania Perelman School of Medicine
Associate Fellow, Center for Public Health Initiatives (CPHI), University of Pennsylvania Perelman School of Medicine
Director, Biostatistics, Bioinformatics, and Data Management Core. Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers
Faculty, Translational Research T32 Training Program in Environmental Health Sciences, University of Pennsylvania Perelman School of Medicine
Associate Director, Center of Excellence in Environmental Toxicology (CEET) Integrative Health Sciences Facility Core (IHSFC) Biostatistics Group
Member, Research Core Facilities Committee, University of Pennsylvania Perelman School of Medicine
Department: Biostatistics and Epidemiology

Contact information
Department of Biostatistics, Epidemiology and Informatics (DBEI)
Center for Clinical Epidemiology and Biostatistics (CCEB)
University of Pennsylvania Perelman School of Medicine
610 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104
Office: 215-573-5946
Fax: 215-573-4865
B.S. (Mathematics)
National Tsing-Hua University, Taiwan, 1995.
Ph.D. (Biostatistics)
Johns Hopkins University, School of Hygiene and Public Health, 2001.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Biostatistics, survival data analysis, longitudinal studies, clinical trials, translational cancer research, biomarker discovery and validation, environmental health sciences, instrument development for psychosocial research

Selected Publications

Ding Z, Ritchie MD, Voight BF, Hwang W-T: Estimating the effect size of a hidden causal factor between SNPs and a continuous trait: a mediation model approach. BMC Bioinformatics 23(1): 420, Oct 2022.

Li Y, Hwang W-T, Maude SL, Teachey DT, Frey NV, Myers RM, Barz Leahy A, Liu H, Porter DL, Grupp SA, Shaw PA : Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies Clinical Cancer Research 28(18): 3940-3949, Sept 2022.

McKeon TP, Anil Vachani, Penning TM, Hwang W-T: Air pollution and lung cancer survival in Pennsylvania Lung Cancer 170: 65-73, Aug 2022 Notes: doi: 10.1016/j.lungcan.2022.06.004.

Camiña N, McWilliams TL, McKeon TP, Penning TM, Hwang W-T.: Identification of spatio-temporal clusters of lung cancer cases in Pennsylvania, USA: 2010-2017. BMC Cancer 22(1): 555, May 2022 Notes: doi: 10.1186/s12885-022-09652-8.

Ren B, Hwang W-T: Modeling post-holiday surge in COVID-19 cases in Pennsylvania counties PLoS One 17(12): e0279371, Dec 2022 Notes: doi: 10.1371/journal.pone.0279371.

Smith AM, Christodouleas JP, Hwang W-T*: Understanding the predictive value of continuous markers for censored survival data using a likelihood ratio approach BMC Medical Research Methodology 19(1): 108, May 2019 Notes: * senior author.

Thompson JC*, Hwang W-T*, Davis C, Deshpande C, Jeffries S, Rajpurohit Y, Krishna V, Smirnov D, Verona R, Lorenzi MV, Langer CJ, Albelda SM. : Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung Cancer 139: 1-8, Jan 2020 Notes: doi: 10.1016/j.lungcan.2019.10.012 * Equal contribution.

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang W-T, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH: CRISPR-engineered T cells in patients with refractory cancer. Science 367(eaba7365), Feb 2020 Notes: doi: 10.1126/science.aba7365 *: Lead statistician (1094 citations to date).

Zhu Y, Hwang W-T, Li Y: Evaluating the effects of design parameters on the performances of phase I trial designs. Contemporary Clinical Trials Communications(15), 100379, May 2019 Notes: doi: 10.1016/j.conctc.2019.100379.

Porter DL, Hwang W-T, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone M, Levine BL, Melenhorst JJ, June CH: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine 7(303): 303ra139, Sep 2015 Notes: *: Second/statistical lead author (1770 citations to date).

Xu R, Mesaros C, Weng L, Snyder NW, Vachani A, Blair IA, Hwang W-T*: Comparison of statistical methods for detection of serum lipid biomarkers for mesothelioma and asbestos exposure. Biomarkers in Medicine 11(7): 547-556, Jul 2017 Notes: *Senior author. The work and funding for the first author (Xu) is supported by Penn Superfund Research Center Biostatistics Core.

Yu D, Hwang W-T: Optimal cutoffs for continuous biomarkers for survival data under competing risks. Communications in Statistics - Simulation and Computation Page: 1-16, Jan 2018 Notes: *: Senior author. doi:10.1080/03610918.2017.1410713.

Fraietta JA*, Lacey SF*, Orlando EJ*, Ambrose DE, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Frey NV, Hwang W-T**, Parakandi H, Gupta M, Huang A, Johnson B, Kulikovskaya I, Levine BL, Liu L, Lundh SM, Pequignot R, Siegel DL, Wang V, Wherry EJ, Xu J, Young RM, Brogdon JL, Bitter H3, Porter DL, June CJ, Melenhorst JJ : Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine 24(5): 563-571, May 2018 Notes: *: Equal contribution, **: Statistical lead (1279 citations to date).

back to top
Last updated: 03/29/2024
The Trustees of the University of Pennsylvania